Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 70

Results For "ARR"

1158 News Found

Apollo launches national program to promote rational use of antibiotics
News | November 18, 2022

Apollo launches national program to promote rational use of antibiotics

Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes


CPhI & P-MEC India expo to encourage cost-effective solutions in India’s march towards a Rs 10.5 lakh crore pharma market by 2030
News | November 17, 2022

CPhI & P-MEC India expo to encourage cost-effective solutions in India’s march towards a Rs 10.5 lakh crore pharma market by 2030

The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees


Lynparza in combination with Abiraterone and prednisone receives positive opinion from EU CHMP
Drug Approval | November 15, 2022

Lynparza in combination with Abiraterone and prednisone receives positive opinion from EU CHMP

First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations


Dr. Lucica Ditiu appreciates India's TB elimination response
Policy | November 11, 2022

Dr. Lucica Ditiu appreciates India's TB elimination response

Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi


Ashland injectable pharmaceutical excipient accepted into FDA Novel Excipient Review Pilot Program
Drug Approval | November 01, 2022

Ashland injectable pharmaceutical excipient accepted into FDA Novel Excipient Review Pilot Program

The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.


Aptar Pharma completes Phase I global injectables expansion program
News | November 01, 2022

Aptar Pharma completes Phase I global injectables expansion program

The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.


Alembic Pharma gets USFDA approval for Glycopyrrolate Injection USP
Drug Approval | November 01, 2022

Alembic Pharma gets USFDA approval for Glycopyrrolate Injection USP

This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.


21.4 lakh TB cases notified in India in 2021
Policy | October 30, 2022

21.4 lakh TB cases notified in India in 2021

Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today


ERES IV acquires a majority stake in Oncodesign Services
News | October 27, 2022

ERES IV acquires a majority stake in Oncodesign Services

Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.


Merck’s PREVYMIS effective for prevention of cytomegalovirus disease in adults post kidney transplantation
Clinical Trials | October 23, 2022

Merck’s PREVYMIS effective for prevention of cytomegalovirus disease in adults post kidney transplantation

Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint